As a critical protein in BCR signal transduction, BTK is an attractive drug target for B-cell malignancies (such as chronic lymphocytic leukemia and mantle cell lymphoma) and autoimmune and inflammatory disorders (Mouhssine et al., 2024). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.